Summary & Overview
HCPCS G9504: Documented Reason for Not Assessing HBV Status Prior to Anti-TNF Therapy
HCPCS Level II code G9504 denotes a documented reason for not assessing hepatitis B virus (HBV) status before initiating anti-TNF therapy, capturing clinical or patient-driven decisions that preclude testing (for example, patient declines testing or therapy is not initiated). Nationally, this code matters for tracking adherence to pre-biologic screening protocols, supporting quality measurement, and documenting risk management in immunomodulatory treatment pathways. Key payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what G9504 represents in clinical workflows, where it is typically applied (outpatient clinics and infusion centers), and how it functions as documentation of a deliberate choice not to assess HBV status prior to anti-TNF therapy. The publication provides benchmarks and policy context where available, explains typical service line placement for pre-therapy risk assessment documentation, and highlights how this code integrates with quality reporting and clinical safety processes. Data not available in the input will be noted where relevant.
Billing Code Overview
HCPCS Level II code G9504 documents a documented reason for not assessing hepatitis B virus (HBV) status prior to initiating anti-TNF therapy. The description covers instances such as the patient not initiating anti-TNF therapy or the patient declining testing, indicating that the HBV status assessment was intentionally not performed and the reason was recorded.
Service type: Pre-therapy clinical documentation / treatment risk assessment
Typical site of service: Outpatient clinic or infusion center where anti-TNF therapy is considered or administered
Clinical & Coding Specifications
Clinical Context
A patient with an autoimmune condition (for example, rheumatoid arthritis) is evaluated by a rheumatology team for initiation of anti–tumor necrosis factor (anti‑TNF) therapy. Prior to biologic initiation, the clinical workflow normally includes screening for latent and chronic infections including hepatitis B virus (HBV). In a documented encounter the clinician records a specific, valid reason for not assessing HBV status prior to starting anti‑TNF therapy — for example, the patient declines testing (patient declined), the patient will not proceed with anti‑TNF therapy (patient not initiating anti‑TNF therapy), an urgent need for treatment precludes testing prior to first dose, or previous reliable recent HBV testing is available but not accessible in the electronic record. The typical site of service is an outpatient specialty clinic (rheumatology or infusion center) or hospital outpatient infusion suite when biologic therapy is being initiated or planned. Documentation in the medical record must state the reason for not performing HBV serology and provide clinical context (patient decision, treatment urgency, existing external results, or contraindication). Billing uses G9504 to indicate a documented reason for not assessing HBV status prior to initiating anti‑TNF therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|